Zacks Investment Research downgraded shares of Prevail Therapeutics (NASDAQ:PRVL) from a buy rating to a sell rating in a research report report published on Saturday, Zacks.com reports.

According to Zacks, “Prevail Therapeutics Inc. is a gene therapy company. It focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company’s product candidate consists of PR001, PR006 and PR004 which are in clinical stage. Prevail Therapeutics Inc. is based in New York. “

PRVL has been the topic of a number of other research reports. Wedbush reissued a buy rating and issued a $20.00 price target on shares of Prevail Therapeutics in a research note on Friday, November 1st. Cowen reissued a buy rating on shares of Prevail Therapeutics in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $16.50.

NASDAQ:PRVL traded up $1.43 during mid-day trading on Friday, reaching $12.45. 7,950 shares of the stock were exchanged, compared to its average volume of 77,364. The business’s fifty day moving average price is $10.90. Prevail Therapeutics has a 1-year low of $7.41 and a 1-year high of $16.90. The company has a quick ratio of 17.05, a current ratio of 17.05 and a debt-to-equity ratio of 0.06.

Prevail Therapeutics (NASDAQ:PRVL) last released its earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.12). Sell-side analysts expect that Prevail Therapeutics will post -2.73 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of PRVL. SG Americas Securities LLC purchased a new position in Prevail Therapeutics in the 2nd quarter worth about $194,000. DekaBank Deutsche Girozentrale purchased a new position in Prevail Therapeutics in the 2nd quarter worth about $615,000. Monashee Investment Management LLC purchased a new position in Prevail Therapeutics in the 2nd quarter worth about $1,188,000. Northern Trust Corp purchased a new position in Prevail Therapeutics in the 2nd quarter worth about $188,000. Finally, Omega Fund Management LLC purchased a new position in Prevail Therapeutics during the 2nd quarter valued at about $8,830,000. 79.28% of the stock is currently owned by hedge funds and other institutional investors.

About Prevail Therapeutics

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Recommended Story: What Does a Sell-Side Analyst Rating Mean?

Get a free copy of the Zacks research report on Prevail Therapeutics (PRVL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.